MiMedx Group, Inc. – NASDAQ:MDXG
MiMedx Group stock price today
MiMedx Group stock price monthly change
MiMedx Group stock price quarterly change
MiMedx Group stock price yearly change
MiMedx Group key metrics
Market Cap | 1.32B |
Enterprise value | 357.77M |
P/E | -10 |
EV/Sales | 1.33 |
EV/EBITDA | -16.99 |
Price/Sales | 1.40 |
Price/Book | -20.85 |
PEG ratio | 0.08 |
EPS | 0.54 |
Revenue | 334.51M |
EBITDA | 56.88M |
Income | 79.91M |
Revenue Q/Q | 18.18% |
Revenue Y/Y | 19.20% |
Profit margin | -11.27% |
Oper. margin | -9.32% |
Gross margin | 81.96% |
EBIT margin | -9.32% |
EBITDA margin | 17% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMiMedx Group stock price history
MiMedx Group stock forecast
MiMedx Group financial statements
$16
Potential upside: 125.35%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 81.25M | 1.2M | 1.48% |
|---|---|---|---|
| Sep 2023 | 81.71M | 6.76M | 8.27% |
| Dec 2023 | 86.83M | 62.68M | 72.19% |
| Mar 2024 | 84.70M | 9.26M | 10.93% |
| Jun 2023 | 176378000 | 189.04M | 107.18% |
|---|---|---|---|
| Sep 2023 | 189022000 | 187.69M | 99.3% |
| Dec 2023 | 239047000 | 96.33M | 40.3% |
| Mar 2024 | 221681000 | 65.95M | 29.75% |
| Jun 2023 | 7.77M | -348K | 4K |
|---|---|---|---|
| Sep 2023 | 12.79M | -649K | 370K |
| Dec 2023 | 10.25M | -481K | -8.94M |
| Mar 2024 | 4.87M | -6.02M | -32.36M |
MiMedx Group alternative data
| Aug 2023 | 867 |
|---|---|
| Sep 2023 | 867 |
| Oct 2023 | 867 |
| Nov 2023 | 867 |
| Dec 2023 | 867 |
| Jan 2024 | 867 |
| Feb 2024 | 867 |
| Mar 2024 | 895 |
| Apr 2024 | 895 |
| May 2024 | 895 |
| Jun 2024 | 895 |
| Jul 2024 | 895 |
MiMedx Group other data
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 0 | 39420 |
| May 2023 | 0 | 90238 |
| Jun 2023 | 100000 | 0 |
| Nov 2023 | 5000 | 0 |
| Feb 2024 | 0 | 61807 |
| Mar 2024 | 0 | 20381 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HULSE WILLIAM FRANK IV officer: General .. | Common Stock | 20,381 | $7.95 | $162,029 | ||
Sale | WHITLOW RICCI S officer: Chief Operating Officer | Common Stock | 15,271 | $8.01 | $122,351 | ||
Sale | WHITLOW RICCI S officer: Chief Operating Officer | Common Stock | 15,493 | $8.07 | $125,075 | ||
Sale | WHITLOW RICCI S officer: Chief Operating Officer | Common Stock | 15,198 | $8.06 | $122,496 | ||
Sale | WHITLOW RICCI S officer: Chief Operating Officer | Common Stock | 15,845 | $8.03 | $127,267 | ||
Purchase | DOUG RICE officer: Chief Financial Officer | Common Stock | 5,000 | $7.16 | $35,785 | ||
Purchase | CAPPER JOSEPH H officer: Chief Executive Officer | Common Stock | 42,025 | $6.5 | $273,331 | ||
Purchase | CAPPER JOSEPH H officer: Chief Executive Officer | Common Stock | 57,975 | $6.33 | $367,098 | ||
Sale | STEIN ROBERT BENJAMIN officer: Presiden.. | Common Stock | 10,365 | $5.95 | $61,630 | ||
Sale | STEIN ROBERT BENJAMIN officer: Presiden.. | Common Stock | 3,607 | $6.15 | $22,172 |
| Patent |
|---|
Grant Utility: Placental tissue component compositions for treatment of skin defects and methods using same Filling date: 30 Nov 2020 Issue date: 26 Jul 2022 |
Grant Filling date: 21 May 2018 Issue date: 19 Jul 2022 |
Grant Utility: Placental tissue grafts modified with a cross-linking agent and methods of making and using the same Filling date: 15 Mar 2013 Issue date: 24 May 2022 |
Application Filling date: 4 Nov 2021 Issue date: 5 May 2022 |
Application Filling date: 10 Jan 2022 Issue date: 28 Apr 2022 |
Application Filling date: 16 Dec 2021 Issue date: 7 Apr 2022 |
Grant Filling date: 18 Oct 2018 Issue date: 1 Feb 2022 |
Grant Filling date: 18 Oct 2018 Issue date: 11 Jan 2022 |
Application Filling date: 17 Jun 2021 Issue date: 23 Dec 2021 |
Application Filling date: 27 May 2021 Issue date: 16 Sep 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 30 Apr 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 30 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Timothy R. Wright (1958) Chief Executive Officer & Director | $1,350,000 |
| Dr. Robert Benjamin Stein M.D., Ph.D. (1951) Executive Vice President of R&D | $842,380 |
Mr. Peter Martin Carlson CPA (1964) Chief Financial Officer | $789,740 |
| Mr. William F. Hulse IV (1974) Gen. Counsel & Sec. | $775,700 |
| Dr. Rohit Kashyap Ph.D. (1971) Executive Vice President & Chief Commercial Officer | $492,690 |
-
What's the price of MiMedx Group stock today?
One share of MiMedx Group stock can currently be purchased for approximately $7.1.
-
When is MiMedx Group's next earnings date?
Unfortunately, MiMedx Group's (MDXG) next earnings date is currently unknown.
-
Does MiMedx Group pay dividends?
No, MiMedx Group does not pay dividends.
-
How much money does MiMedx Group make?
MiMedx Group has a market capitalization of 1.32B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 20.03% to 321.48M US dollars.
-
What is MiMedx Group's stock symbol?
MiMedx Group, Inc. is traded on the NASDAQ under the ticker symbol "MDXG".
-
What is MiMedx Group's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MiMedx Group?
Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the following people:
- Mr. Timothy R. Wright Chief Executive Officer & Director(age: 67, pay: $1,350,000)
- Dr. Robert Benjamin Stein M.D., Ph.D. Executive Vice President of R&D(age: 74, pay: $842,380)
- Mr. Peter Martin Carlson CPA Chief Financial Officer(age: 61, pay: $789,740)
- Mr. William F. Hulse IV Gen. Counsel & Sec.(age: 51, pay: $775,700)
- Dr. Rohit Kashyap Ph.D. Executive Vice President & Chief Commercial Officer(age: 54, pay: $492,690)
-
How many employees does MiMedx Group have?
As Jul 2024, MiMedx Group employs 895 workers.
-
When MiMedx Group went public?
MiMedx Group, Inc. is publicly traded company for more then 17 years since IPO on 12 Feb 2008.
-
What is MiMedx Group's official website?
The official website for MiMedx Group is mimedx.com.
-
Where are MiMedx Group's headquarters?
MiMedx Group is headquartered at 1775 West Oak Commons Court, NE, Marietta, GA.
-
How can i contact MiMedx Group?
MiMedx Group's mailing address is 1775 West Oak Commons Court, NE, Marietta, GA and company can be reached via phone at +7 706519100.
-
What is MiMedx Group stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for MiMedx Group in the last 12 months, the avarage price target is $16. The average price target represents a 125.35% change from the last price of $7.1.
MiMedx Group company profile:
MiMedx Group, Inc.
mimedx.comNASDAQ
895
Biotechnology
Healthcare
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Marietta, GA 30062
CIK: 0001376339
ISIN: US6024961012
CUSIP: 602496101
